Today, prominent investor rights law firm Bernstein Litowitz Berger & Grossmann LLP (“BLB&G”) filed a class action lawsuit in the U.S. District Court for the Southern District of New York alleging violations of the federal securities laws by Dentsply Sirona Inc. (“Dentsply” or the “Company”) and certain of the Company’s current and former executives (collectively, “Defendants”). The action is brought on behalf of all purchasers of Dentsply common stock between May 6, 2021, and November 6, 2024, inclusive (the “Class Period”). This case is related to two previously filed securities class actions pending against Dentsply captioned North Collier Fire Control and Rescue District Firefighters Retirement Plan v. Dentsply Sirona Inc., No. 24-cv-9083 (S.D.N.Y.) (“North Collier”), which asserts a class period of December 1, 2022 through November 6, 2024; and Calvin v. Dentsply Sirona Inc., No. 24-cv-9764 (S.D.N.Y.), which asserts a class period of February 28, 2022 through November 6, 2024.

BLB&G filed this action on behalf of its client, Key West Police & Fire Pension Fund, and the case is captioned Key West Police & Fire Pension Fund v. Dentsply Sirona Inc., No. 24-cv-9819 (S.D.N.Y.). The complaint is based on an extensive investigation and a careful evaluation of the merits of this case. A copy of the complaint is available on BLB&G’s website by clicking here.

Dentsply’s Alleged Fraud

Dentsply is a manufacturer of dental products and technology. The Company produces a wide array of dental supplies, ranging from anesthetics, plaque and gum disease prevention, tooth polishers, and artificial teeth. On December 31, 2020, prior to the start of the Class Period, Dentsply acquired Byte LLC (“Byte”), a direct-to-consumer clear aligner company, for $1.04 billion.

The complaint alleges that, throughout the Class Period, Defendants made numerous materially false and misleading statements and omissions concerning Byte’s aligner device, including the quality of the product and its reception by customers. Specifically, Defendants repeatedly represented to investors that Byte customers were overseen by an “expansive nationwide network of independent licensed dentists and orthodontists” to ensure compliance with the rules and regulations pertaining to dentistry, that Byte’s customer satisfaction scores were “high” and “improving,” and that a “focused funnel” of targeted potential customers led to high rates of conversion to paying customers. As a result of these misrepresentations, Dentsply common stock traded at artificially inflated prices throughout the Class Period.

In reality, Byte aligners had been causing serious injuries to patients since at least May 2021. Furthermore, Byte did not have a system in place to report these injuries to the Food and Drug Administration, despite being required to do so within 30 days of learning of them. Finally, rather than a “focused funnel” of high-quality potential customers, sales employees and overseeing dentists were incentivized to enroll “contraindicated” patients who were medically ineligible for Byte treatment, improperly driving up conversion rates.

The truth began to emerge on October 24, 2024, when Dentsply announced that it was suspending the sale and marketing of Byte Aligner Systems and Impression Kits “while the Company conducts a review of certain regulatory requirements related to these products.” The Company further announced that it expected to record a goodwill impairment of $450 to $550 million. In response to these disclosures, Dentsply common stock declined by $1.10 per share, or 4.5%.

Then, on November 7, 2024, Dentsply adjusted its earnings per share (“EPS”) outlook downwards by approximately 8%, due in part to the suspension of Byte. The Company told investors that it was not in a position to make a decision concerning Byte but was considering discontinuing some or all of the Byte business. Dentsply also confirmed an impairment to goodwill of $495 million in relation to Byte. Additionally, the Company admitted that Byte was one of a few “significant hurdles” to achieving the Company’s long-term EPS targets. These disclosures caused Dentsply common stock to decline by $6.72 per share, or more than 28%.

The filing of this action does not alter the previously established deadline to seek appointment as Lead Plaintiff. Pursuant to the November 26, 2024 notice published in connection with the North Collier action, under the Private Securities Litigation Reform Act of 1995, investors who purchased Dentsply common stock during the Class Period may, no later than January 27, 2025, seek to be appointed as Lead Plaintiff for the Class. Any member of the proposed Class may seek to serve as Lead Plaintiff through counsel of their choice, or may choose to do nothing and remain a member of the proposed Class.

If you wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact Scott R. Foglietta of BLB&G at 212-554-1903, or via e-mail at scott.foglietta@blbglaw.com.

About BLB&G

BLB&G is widely recognized worldwide as a leading law firm advising institutional investors on issues related to corporate governance, shareholder rights, and securities litigation. Since its founding in 1983, BLB&G has built an international reputation for excellence and integrity and pioneered the use of the litigation process to achieve precedent-setting governance reforms. Unique among its peers, BLB&G has obtained several of the largest and most significant securities recoveries in history, recovering over $40 billion on behalf of defrauded investors. More information about the firm can be found online at www.blbglaw.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241219230074/en/

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.